Login
$ELUT
$0.82 +$0.00 (0.35%) Live

$ELUT 8-K SEC Filings

Filed On Filing
05 Nov 2026 8-K: Results of Operations and Financial Condition

Elutia Reports Third Quarter 2026 Results: As Plastic Surgeons Cite Infection Risk in Every Breast Research Session During National Meeting, NXT-41x Heads to FDA This Quarter, Fully Funded Through Launch

21 Aug 2026 8-K: Completion of Acquisition or Disposition of Assets; Regulation FD Disclosure

On August 17, 2026, Elutia Inc. (the “Company”) completed the previously announced sale of its Women’s Health segment (the “SimpliDerm Business”) to Cellution Biologics Inc. (“Cellution Biologics” or the “Buyer”). The sale (the “SimpliDe...

13 Aug 2026 8-K: Results of Operations and Financial Condition

Funded through launch: secured up to $26 million of capital without an equity offering

07 Aug 2026 8-K: Notice of Delisting or Failure to Satisfy a Listing Rule

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

20 Jul 2026 8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure

CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (i) NOT MATERIAL AND (ii) THE REGISTRANT CUSTOMARILY AND ACTUALLY TR...

16 Jun 2026 8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

14 May 2026 8-K: Results of Operations and Financial Condition

Elutia Reports First Quarter 2026 Results and Highlights NXT-41x Progress Toward $1.5 Billion U.S. Plastic and Reconstructive Surgery Market

11 Mar 2026 8-K: Results of Operations and Financial Condition

– Base biologic matrix NXT-41 submitted to FDA; on track for anticipated FDA clearance in second half of 2026 and full NXT-41x clearance in 1H27 –

09 Mar 2026 8-K: Departure/Election of Directors or Officers; Compensation

The purpose of the Elutia Inc. 2026 Inducement Award Plan (as it may be amended or restated from time to time, the “Plan”) is to enhance the ability of Elutia Inc. (the “Company”) and its Subsidiaries to attract, retain and motivate pers...

04 Mar 2026 8-K: Other Events

GAITHERSBURG, Md., March 4, 2026 — Elutia Inc. (Nasdaq: ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that it has received notice from Nasdaq that Elutia has regained compliance with...

12 Jan 2026 8-K: Results of Operations and Financial Condition

Fourth quarter revenue up 16% year-over-year, $26.9M of secured debt eliminated, and total cash and escrowed proceeds of $44.3M at year-end

02 Jan 2026 8-K: Notice of Delisting or Failure to Satisfy a Listing Rule

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

12 Nov 2025 8-K: Notice of Delisting or Failure to Satisfy a Listing Rule

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

06 Nov 2025 8-K: Results of Operations and Financial Condition

Elutia Reports Third Quarter 2025 Financial Results; Closes $88 Million Sale of BioEnvelope Business to Boston Scientific Corporation; Funds NXT-41x Development

14 Oct 2025 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

Industry leader brings 40 years of executive and board experience across the global medical technology sector

07 Oct 2025 8-K: Entry into a Material Definitive Agreement; Completion of Acquisition or Disposition of Assets +2 more

This Consent, Release and Amendment No. 3 to Royalty Agreement (this “Amendment”) is dated as of October 1, 2025 (the “Effective Date”), by and between Elutia Med LLC, a Delaware limited liability company (formerly known as Aziyo Med, LL...

09 Sep 2025 8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure

CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) THE REGISTRANT CUSTOMARILY AND ACTUALLY TREATS SUCH INFORMATION AS CONFIDENTIAL. SUCH EXCLUDED INFORMATION HAS BEEN MARKED WI...

20 Aug 2025 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation

THIS FIFTH AMENDMENT TO CREDIT AGREEMENT (this “Amendment”), dated as of August 14, 2025, is entered into by and among ELUTIA INC., a Delaware corporation (f/k/a Aziyo Biologics, Inc.) (“Borrower”), each of the undersigned financial inst...

14 Aug 2025 8-K: Results of Operations and Financial Condition

EluPro™ Q2 revenue up 49% sequentially; Elutia advances next-generation drug-eluting biomatrix for breast reconstruction

04 Jun 2025 8-K: Submission of Matters to a Vote of Security Holders

On May 29, 2025, Elutia Inc. (the “Company”) held its annual meeting of stockholders. A total of 29,585,703 shares of the Company’s Class A common stock were present in person or represented by proxy at the meeting, representing approxim...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support